The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2389-2394

  Yamamoto, Yusuke ^a   Ikoma, Hisashi ^a   Morimura, Ryo ^a   Konishi, Hirotaka ^a   Murayama, Yasutoshi ^a   Komatsu, Shuhei ^a   Shiozaki, Atsushi ^a   Kuriu, Yoshiaki ^a   Kubota, Takeshi ^a   Nakanishi, Masayoshi ^a   Ichikawa, Daisuke ^a   Fujiwara, Hitoshi ^a   Okamoto, Kazuma ^a   Sakakura, Chouhei ^a   Ochiai, Toshiya ^b   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Lymph node metastasis; Lymph node ratio; Pancreatectomy; Pancreatic cancer

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; HUMAN; JAPANESE (PEOPLE); LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CANCER; SURVIVAL; SURVIVAL TIME; KAPLAN MEIER METHOD; LYMPH NODE; MORTALITY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

LYMPH NODE METASTASIS; LYMPH NODE RATIO; PANCREATECTOMY; PANCREATIC CANCER;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84902961371     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cameron JL, Riall TS, Coleman J and Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg 244: 10-15, 2006.
2. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R and Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28: 219-230, 2004.
3. Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A and Calgaro M: Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 138: 1316-1322, 2003.
4. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM and Farnell MB: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247: 456-462, 2008.
5. Yamamoto Y, Shimada K, Takeuchi Y, Sofue K, Shibamoto K, Nara S, Esaki M, Sakamoto Y, Kosuge T and Hiraoka N: Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. World J Surg 36: 2192-2201, 2012.
6. Yamamoto Y, Sakamoto Y, Ban D, Shimada K, Esaki M, Nara S and Kosuge T: Is celiac axis resection justified for T4 pancreatic body cancer? Surgery 151: 61-69, 2012.
7. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD and Yeo CJ: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10: 1199-1210, 2006.
8. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S and Trede M: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27: 324-329, 2003.
9. Lim JE, Chien MW and Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237: 74-85, 2003.
10. Brennan MF, Kattan MW, Klimstra D and Conlon K: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240: 293-298, 2004.
11. Truong PT, Berthelet E, Lee J, Kader HA and Olivotto IA: The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 103: 2006-2014, 2005.
12. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ and Haller DG: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23: 8706-8712, 2005.
13. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, Cummings B, Gunderson L, Macdonald JS and Mayer RJ: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19: 157-163, 2001.
14. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ and Haller DG: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003.
15. Inoue K, Nakane Y, Iiyama H, Sato M, Kanbara T, Nakai K, Okumura S, Yamamichi K and Hioki K: The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 9: 27-34, 2002.
16. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma 14th Edition. Tokyo: Kanehara & Co. Ltd., 2010.
17. Sobin LH: TNM: Classifcation of Malignant Tumours. 6th Edition. Wittekind C (ed.). International Union Against Cancer (UICC). New York, NY: Wiley, pp. 93-96, 2002.
18. Japan Pancreas Society: Classification of Pancreatic Carcinoma, Second English Edition. Kanehara: Tokyo, 2003.
19. Berger AC, Watson JC, Ross EA and Hoffman JP: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 70: 235-240, 2004.
20. Sierzega M, Popiela T, Kulig J and Nowak K: The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 33: 240-245, 2006.
21. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ and Choti MA: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141: 610-618, 2007.
22. Shimada K, Sano T, Sakamoto Y and Kosuge T: Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol 13: 1569-1578, 2006.
23. Schwarz RE and Smith DD: Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 13: 1189-1200, 2006.
24. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda Y, Sakoda K, Kinoshita T, Yasui K, Shimada H and Katoh H: Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: Long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19: 230-241, 2012.
25. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K and Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of t he pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228: 508-517, 1998.
26. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA and Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236: 355-366, 2002.
27. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, Abrams RA, Laheru D, Hruban RH and Yeo CJ: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma-part 3: update on 5-year survival. J Gastrointest Surg 9: 1191-1204, 2005.
28. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N and Sargent DJ: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduo-denectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138: 618-630, 2005.
29. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA and Pawlik TM: Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15: 165-174, 2008.
30. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ and Choti MA: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141: 610-618, 2007.
31. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT and Makowiec F: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13: 1337-1344, 2009.